AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD

      Project: Research project

      Project Details

      StatusFinished
      Effective start/end date4/2/138/8/13

      Funding

      • Children's Hospital of Philadelphia (COG AAML1031)
      • Bayer HealthCare Pharmaceuticals, Inc. (COG AAML1031)